[HTML][HTML] Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai, J Zhao, TT An… - Chinese journal of …, 2016 - Springer
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai, J Zhao, TT An… - Chinese Journal of …, 2016 - go.gale.com
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai, J Zhao, TT An… - Cancer …, 2016 - infona.pl
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
JY Yu, SF Yu, SH Wang, H Bai, J Zhao… - Chinese Journal of …, 2016 - europepmc.org
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai… - Chinese journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
[HTML][HTML] Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai, J Zhao… - Chinese Journal of …, 2016 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
[HTML][HTML] Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai… - Chinese …, 2016 - cancercommun.biomedcentral.com
Epidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19
del) and exon 21 L858R point mutation (L858R mutation), are strong predictors of the …
del) and exon 21 L858R point mutation (L858R mutation), are strong predictors of the …
Clinical outcomes of EGFR‐TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai, J Zhao… - Cancer …, 2016 - Wiley Online Library
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors …
[PDF][PDF] Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai, J Zhao, TT An, JC Duan… - 2016 - core.ac.uk
Background: Epidermal growth factor receptor (EGFR) mutations, including a known exon
19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong …
19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong …
[PDF][PDF] Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
JY Yu, SF Yu, SH Wang, H Bai, J Zhao, TT An, JC Duan… - 2016 - cyberleninka.org
Background: Epidermal growth factor receptor (EGFR) mutations, including a known exon
19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong …
19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong …